BEDFORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc., a leading company in radiopharmaceuticals, has announced the upcoming presentation of new data at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in New Orleans, LA, from June 21-24, 2025. The presentations will highlight two oncology radiodiagnostic agents. Notably, the session titled "First Clinical Evaluation of 68Ga-LNTH-1363S, a Novel FAP-Targeting Radiopharmaceutical for PET Imaging," will be presented by Ida Sonni from the University of California, Los Angeles, on June 23, 2025. Additionally, Gyu Seong Heo from Washington University will present on the preclinical assessment of 64Cu-LNTH-1363S for FAP PET imaging in cardiovascular applications on June 24, 2025. The findings will be shared with the medical community during these sessions, contributing to advancements in radiopharmaceutical applications in oncology and cardiovascular imaging.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.